An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia
Completed
- Conditions
- Schizophrenia
- Registration Number
- NCT01634542
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This multicenter, prospective, non-interventional study will evaluate the prevalence and characteristics of patients with persistent symptoms of schizophrenia and the course of their illness over 24 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1433
Inclusion Criteria
Patients:
- Adult patients, >/= 18 years of age
- Diagnosis of schizophrenia according to Diagnostic and Statistical Manual for Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) or International Classification of Diseases, 10th revision (ICD-10)
Caregivers:
- Age >/= 18 years
- Family member or friend of the patient, who spends at least 4 hours a week with the patient
Exclusion Criteria
- Acute psychotic exacerbation in the 3 months prior to the baseline observation (e.g. hospitalization or increased psychiatric care in order to prevent hospitalization)
- Enrolled in an interventional study at the baseline observation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Course of illness: Change in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scores from baseline to Month 24
- Secondary Outcome Measures
Name Time Method Frequency/characteristics (PANSS) of patients with diagnosis of schizophrenia of >/= 12 months duration before baseline at screening (approximately 18 months) Medical resource utilization/costs 24 months Duration/severity of symptoms of schizophrenia according to Personal Social Performance Scale (PSP) / Health Related Quality of Life (HRQoL) questionnaire 24 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do dopamine and glutamate dysregulation mechanisms correlate with persistent schizophrenia symptoms in NCT01634542?
What comparative effectiveness data exist for standard antipsychotics versus novel therapies in managing persistent schizophrenia symptoms?
Which biomarkers (e.g., neuroimaging, genetic markers) predict treatment resistance in NCT01634542's schizophrenia cohort?
What adverse event profiles are reported for antipsychotic regimens in patients with persistent schizophrenia symptoms from NCT01634542?
How do Roche's investigational compounds or combination strategies address persistent schizophrenia subtypes identified in NCT01634542?